title: Second trimester abortion in women with and without previous uterine scar: Eleven years experience from a developing country.
abstract: OBJECTIVE
  To study the safety of second trimester abortion in women with previous uterine scar.
  
  
  METHODS
  We screened the records of 518 women who underwent an abortion between 12 and 20 weeks' gestation at the Postgraduate Institute of Medical Education and Research, Chandigarh, India, from January 2000 to December 2010. Methods used for abortion were: (i) vaginal misoprostol with or without pre-treatment with mifepristone, and (ii) intracervical dinoprostol gel or vaginal misoprostol ± extra-amniotic saline ± oxytocin infusion. Seventeen women, aborted by means of a hysterotomy, were excluded from further analysis.
  
  
  RESULTS
  Of the remaining 501 women, 44 had a uterine scar (Group 1) and 457 had none (Group 2). In Group 1, 40/44 (91%) and in Group 2, 452/457 (99%) women aborted successfully. The mean induction-abortion interval (IAI) was similar in the two groups (15.03 ± 10.69 hours and 12.52 ± 9.0 hours in Groups 1 and 2, respectively; p = 0.083). There were three uterine ruptures, 1/44 (2%) in group 1 and 2/457 (0.4%) in group 2 (p = 0.132, NS); all three women had received mifepristone followed by vaginal misoprostol.
  
  
  CONCLUSIONS
  In women with a scarred uterus, midtrimester abortion may be successfully achieved using any of the aforementioned regimens.
authors.affiliation: Department of Obstetrics and Gynaecology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
authors.forename: Neelam
authors.initials: N
authors.lastname: Choudhary
authors.forename: Rashmi
authors.initials: R
authors.lastname: Bagga
authors.forename: Ainharan
authors.initials: A
authors.lastname: Raveendran
authors.forename: Subhas Chandra
authors.initials: SC
authors.lastname: Saha
authors.forename: Lakhbir Kaur
authors.initials: LK
authors.lastname: Dhaliwal
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage / Q000009:adverse effects; D000028:Abortion, Induced / Q000009:adverse effects* / Q000706:statistics & numerical data; D000328:Adult; D016022:Case-Control Studies; D002921:Cicatrix / Q000473:pathology*; D003906:Developing Countries; D015237:Dinoprost / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007194:India / Q000453:epidemiology; D015735:Mifepristone / Q000008:administration & dosage / Q000009:adverse effects; D016595:Misoprostol / Q000008:administration & dosage / Q000009:adverse effects; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D012189:Retrospective Studies; D014591:Uterine Diseases / Q000473:pathology*; D014597:Uterine Rupture / Q000453:epidemiology* / Q000209:etiology
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D016595:Misoprostol; D015735:Mifepristone; D015237:Dinoprost